We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A digest of the Evidence-Based Clinical Practice Guideline for Nephrotic Syndrome 2020.
- Authors
Wada, Takehiko; Ishimoto, Takuji; Nakaya, Izaya; Kawaguchi, Takehiko; Sofue, Tadashi; Shimizu, Sayaka; Kurita, Noriaki; Sasaki, Sho; Nishiwaki, Hiroki; Koizumi, Masahiro; Saito, Shoji; Nishibori, Nobuhiro; Oe, Yuji; Yoshida, Mai; Miyaoka, Yoshitaka; Akiyama, Shin'ichi; Itano, Yuya; Okazaki, Masaki; Ozeki, Takaya; Ichikawa, Daisuke
- Abstract
Treatment-resistant MN If the patient does not achieve complete remission or incomplete remission type I after 4 weeks of corticosteroid monotherapy, additional treatment should be considered. 2) Initial treatment Oral prednisolone is administered once daily, starting at 0.8-1 mg/kg/day (maximum 60 mg/day), for 2-4 weeks as the initial treatment for primary FSGS with nephrotic syndrome. Grades of recommendations: 1 - "We recommend" 2 - "We suggest" None Definitions, underlying diseases, pathophysiology Definitions/diagnosis Nephrotic syndrome is a clinical syndrome characterized by severe proteinuria and hypoproteinemia (or hypoalbuminemia). If the patient does not achieve complete remission or incomplete remission type I after 6 months of conservative therapy, consider switching to corticosteroid monotherapy or combination treatment with corticosteroids and immunosuppressive agents.
- Subjects
NEPHROTIC syndrome; DYSLIPIDEMIA; ACUTE kidney failure; FOCAL segmental glomerulosclerosis
- Publication
Clinical & Experimental Nephrology, 2021, Vol 25, Issue 12, p1277
- ISSN
1342-1751
- Publication type
Academic Journal
- DOI
10.1007/s10157-021-02098-5